Sanofi posts flat 1st-qtr sales but earnings up and beat expectations

29 April 2016

French pharma major Sanofi (Euronext: SAN) today posted first-quarter 2016 financials, with sales of 8.54 billion euros ($9.47 billion), almost flat (+0.7%) from last year or down 1.9% on a constant exchange rate basis. This was below analysts’ consensus forecast for 8.63 billion euros. The company’s shares were down 3.28% at 73.69 euros in late morning trading.

Earnings per share were up 1.5%, or 5.3% on a CER basis, at 1.34 euros, versus expectations for 1.29 euros. Net income for the quarter dipped 0.2% (+3.5% at constant exchange rates) at 1.72 billion euros.

Full-year 2016 guidance

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical